CLDX Q1 2022 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$174,000-74.6% YoY

Gross Profit

-$17M-9702.3% margin

Operating Income

-$23M-13366.1% margin

Net Income

-$23M-13247.1% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-47.9%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$424M

Total Liabilities

$26M

Stockholders' Equity

$398M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$174,000	$685,000	-74.6%
Gross Profit	-$17M	-$12M	-40.3%
Operating Income	-$23M	-$17M	-39.8%
Net Income	-$23M	-$17M	-39.4%

Revenue Segments

Contracts and grants

$144,00083%

Product development and licensing agreements

$30,00017%